Pathway / Myocardial injury (shared endpoint)

Myosin Light Chain 2

MYL2gene

Cardiac MYL2 release reflects myocardial injury and cardiomyocyte necrosis/apoptosis post-MI.

Pathway placement

Cascade stepMyocardial injury (shared endpoint)

Confidencemedium

RationaleCardiac myosin regulatory light chain; marker of cardiomyocyte structural damage.

Druggability

DruggableYes

Known drugs / candidates3

Small-molecule tractableYes

Antibody tractableNo

EnsemblENSG00000111245

Type I vs non-Type I discrimination

ScoresLow-confidence (proxy)

R — rupture / Type-I

C — non-Type-I

A — assay feasibility

E — evidence strength

T1DI (composite)

Specificity differential (R−C)-33.1

Non-Type-I axis panel

Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.

No non-Type-I axis evidence retrieved.

Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.

Specimen

Whole blood — gene is not a circulating analyte; measure protein product or genotype

Collection tube

K2-EDTA whole blood (lavender-top)

Method / principle

SNP genotyping / sequencing; or immunoassay of encoded protein

Reagent / substrate

Allele-specific primers/probes (TaqMan) or NGS panel; or antibody for protein

Platform

qPCR / NGS / array

Turnaround · availability

Send-out · Genotyping widely available; protein assay variable

Human genetic evidence

GWAS associations

Traits: myocardial infarction

Literature evidence(0)

No direct literature mentions harvested; included via genetic/target evidence.